NeoGenomics (NASDAQ: NEO) reported Q2 EPS of $0.01, in-line with the analyst estimate of $0.01. Revenue for the quarter came in at $20.7 million versus the consensus estimate of $19.84 million.

For earnings history and earnings-related data on NeoGenomics (NEO) click here.